@mmv.org
A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
@mmv.orgWhere medicines are made impacts who can access them.
Africa is heavily reliant on imports for the medicines needed to fight #malaria.
MMV works with African manufacturers and Africa CDC to strengthen local production and bring medicines closer to patients. bit.ly/4zc2X4m
@mmv.orgWhat can investments in global health make possible?
Through the EDCTP, EU investments advance new health tools, build scientific capacity & attract additional funding, with every €1 mobilizing more than €1 from other sources.
Read our paper: bit.ly/4xKn21U
@mmv.orgWhen resources are under pressure, innovation becomes even more important.
Drug and insecticide resistance, climate change and conflict threaten #malaria progress.
New tools can keep us ahead of resistance, simplify care & make the most of limited resources bit.ly/4xCEkwB
@mmv.orgThere are places we expect #malaria transmission. Germany isn't one of them.
Cases have appeared near Frankfurt Airport. As temps rise, transmission conditions are changing.
A reminder that reducing malaria everywhere strengthens global health security. bit.ly/3VVJBSL
@mmv.orgWhat keeps progress against #malaria moving?
In Liverpool, @malarianomoreuk.bsky.social ambassador Gab Astorga put that question to malaria scientists & global health experts.
See what they had to say
@mmv.orgFollowing encouraging Phase 2a results, MMV will lead the next phase of cabamiquine's development.
Long-acting cabamiquine, with potential to become a single-dose treatment or prevention option, could help address drug resistance & block transmission: bit.ly/4ypoy9x
@mmv.orgPNG shoulders a disproportionate share of the Indo-Pacific's #malaria burden.
Closing the gap means understanding why progress is harder in some settings vs others.
In PNG, MMV met with partners & communities to explore the strategies and tools needed to accelerate elimination.
@mmv.orgThe Malaria Science Index shows how investment in #malaria R&D strengthens global health security and delivers #innovation beyond malaria.
It also shows how UK science benefits from international collaboration.
Sustained investment is key to elimination: bit.ly/47iA8HC
@mmv.orgEach breakthrough in global health starts with a partnership.
The UK is committing more than £100m to product development partnerships (PDPs). For #malaria, sustained investment in PDPs like MMV can help make the next breakthroughs possible.
Read more: bit.ly/4he33kP
@mmv.orgOne dose to cure #malaria.
That's the ambition behind WANECAM3, an Africa-Europe consortium developing new tools to change how we fight the disease.
Prof. Abdoulaye Djimdé & his team in Mali are providing the scientific leadership to help make it happen: bit.ly/4cS0Dag
@mmv.orgWhat will it take to end #malaria?
New tools that can simplify care. Single-dose cures and long-acting prevention could become elimination accelerators, taking us closer to the finish line.
Sustained investment can help get them there.
@mmv.org#ClimateChange is no longer simply a future threat, but a reality we need to manage and adapt to.
For #malaria, building resilience is critical. This means developing simpler medicines that are easier to deliver and use, while strengthening health systems and supply chains.
@mmv.org#Malaria treatment and prevention needs vary by patient, context and setting.
A new review explores how #innovation must respond, from simplifying treatment and providing longer-lasting protection to staying ahead of drug resistance.
Read more: bit.ly/46m7KUO
@mmv.orgDifferent patients need medicines designed for their particular needs.
Coartem® Baby, the first antimalarial developed for newborns and young infants weighing 2–5 kg, is now included in the WHO Guidelines for #malaria, supporting broader access.
Read more: bit.ly/4iqa5Fr
@mmv.orgDoes your organization have insights into how AI can improve clinical trial design and documentation?
MMV, @dndi.org and @gardp.bsky.social are mapping AI solutions for clinical study design, operations and medical writing.
Submission deadline: 7 October
Learn more: bit.ly/3UMwkeW
@mmv.orgWomen should be protected through research, not from it.
Healthcare decisions need evidence, but pregnant & breastfeeding women have historically been excluded from clinical research, leaving critical data gaps.
Read our recommendations for ICH E21: bit.ly/3SKgP6C
@mmv.org#Malaria prevalence in Nigeria among children aged 6–59 months has declined by nearly 64% over the past 15 years.
Sustained investment in prevention tools like SMC, treatment, surveillance and public awareness has helped drive this progress.
Learn more: bit.ly/4qAN44B
@mmv.orgMMV expresses profound sadness at the news of Vasee Moorthy’s untimely passing – we have lost an exceptional champion of global health. We will miss him sorely and send our deepest condolences to his myriad friends and his beloved family.
@mmv.orgMMV has launched a request for information to identify organizations based in or operating in malaria-endemic countries for a new request for information on #malaria market intelligence and evidence generation.
Deadline: 14 October
Learn more: bit.ly/4cbgujY
@mmv.orgThe Africa–Europe WANECAM3 consortium has launched to advance next-generation #malaria treatments.
Through Phase 2 & 3 trials, it aims to advance a single-dose cure to simplify treatment, improve adherence & address antimalarial drug resistance.
Read more bit.ly/4x1j0kk
